| Case Number | 7260 |
| Request Date | 11/02/2020 |
| Completion Date | 04/02/2021 |
Details of the Request
For Rheumatology /Dermatology / Gastroenterology
Is the branded biosimilar AMGEVITA listed on your formulary?
Please complete the number of patients prescribed with the following products in the last 12 months within the Rheumatology, Dermatology and Gastroenterology departments:
Product/place in the adalimumab therapy pathway
- AMGEVITA first-line
- AMGEVITA second-line
- HUMIRA first-line
- HUMIRA second-line
- HYRIMOZ first-line
- IMRALDI first-line
How many patients receive the listed therapies as a first or second treatment once they reach the biologic / biosimilar part of their treatment pathway.
Please complete the table below:
Rheumtology:
- Rheumatoid arthritis
- Ankylosing spondylitis
Dermatology:
- Psoriasis
- Psoriatic arthritis
Gastroenterology
- Crohn’s disease
- Ulcerative colitis
Are any local guidelines followed that recommend earlier use of anti-TNF biologics / biosimilars in the treatment pathway?
Are there occasions where patients can receive adalimumab outside of NICE / SMC / AWMSG / National criteria?
What is the contractual agreement for seeing and treating patients with anti-TNF biologics between you and your referring CCGs / Health Boards?
- Contractual agreement
- Block contracts
Details of the Response
Question 1
| Rheumatology | Dermatology | Gastroenterology | |
| Is the branded biosimilar AMGEVITA listed on your formulary? | Yes | No, it will be updated | Yes |
Question 2
Please complete the number of patients prescribed with the following products in the last 12 months within the Rheumatology, Dermatology and Gastroenterology departments:
| Product/place in the adalimumab therapy pathway* | Rheumatology | Dermatology | Gastroenterology |
| AMGEVITA first-line | N/A | N/A | N/A |
| AMGEVITA second-line | 0 | 0 | 0 |
| HUMIRA first-line | N/A | N/A | N/A |
| HUMIRA second-line | 101 | 37 | 74 |
| HYRIMOZ first-line | N/A | N/A | N/A |
| IMRALDI first-line | 121 | 7 | 46 |
* How many patients receive the listed therapies as a first or second treatment once they reach the biologic/biosimilar part of their treatment pathway. For example, according to the NICE Pathway, psoriasis patients should receive topical therapy, then systemic non-biological therapy, then systemic biological therapy. We would like to know which therapies are received first and second in the biological therapy part of the pathway.
Question 3
Are any local guidelines followed that recommend earlier use of anti-TNF biologics/ biosimilars in the treatment pathway?
No
Are there occasions where patients can receive adalimumab outside of NICE / SMC / AWMSG / National criteria?
No
Question 4
What is the contractual agreement for seeing and treating patients with anti-TNF biologics between you and your referring CCGs / Health Boards?
- Block contracts = No
- Fixed price on a patient-by-patient basis = Yes



